Samabriva: Revolutionizing Precision Biomanufacturing with €4 Million Fundraising Round

In an exciting development for the biotechnology industry, French company Samabriva has successfully completed a Series-A round of financing, securing an investment of nearly €4 million. With its innovative plant-based bioproduction process, Samabriva aims to transform the production of high-value molecules for the pharmaceutical and cosmetic sectors.

The fundraising round saw the participation of several specialist biotech business angels who not only provided financial investment but also bring valuable knowledge and expertise to help propel Samabriva to become a leading Contract Development and Manufacturing Organization (CDMO). The company's immediate focus will be on the production of Active Pharmaceutical Ingredients (API) using confined and controlled plant-based expression systems.

Lead investors like Noshaq and Investsud Tech have now joined the funding round, which will accelerate Samabriva's growth. With this investment, the company will be able to establish its first industrial production site in the Liège region of Belgium, taking advantage of the exceptional biotech ecosystem there while maintaining its research center in France. The funding will expedite the deployment of Samabriva's technology and facilitate its transformation into a fully-fledged CDMO.

Marina Guillet, CEO of Samabriva, expressed her delight at the support received from leading biotech investors and highlighted the company's position to meet the needs of the rapidly growing API market in the pharmaceutical sector.

Eric Brandt, Investment Manager at Noshaq, recognized Samabriva's position at the cutting edge of plant-based biotechnology and the increasing appeal of growing plants in bioreactors due to their sustainability, stability, and consistency. He emphasized the excitement of being part of Samabriva's journey in meeting the growing demand for high-value molecules.

Pascal Lizin, Chairman of Samabriva, described the establishment of the company's first production site in Belgium as a significant milestone. The investment will not only enhance API production capabilities but also accelerate international business development. Additionally, the funding will enable the expansion of Samabriva's R&D center in Amiens, France, dedicated to developing new production processes for high-value products, ultimately contributing to addressing critical public health issues in the global pharmaceutical industry.

Samabriva is a plant-based biotechnology company that has successfully developed a proprietary bioproduction platform utilized by the pharmaceutical and cosmetics industry. The company's innovative and flexible system combines the advantages of plant-based systems (low cost, safe, serum- and animal-free) with traditional bioproduction in large-scale bioreactors. This enables continuous, reliable, and environmentally sustainable manufacture of a wide range of high-value molecules throughout the year, regardless of location.

Currently, the production of secondary metabolites, such as natural active molecules, lacks local scalable and sustainable production processes. Extracting these compounds from plants grown in fields yields very small amounts, making the process costly and environmentally unsustainable. Samabriva's technology offers a compelling solution to address these challenges.

Similarly, the manufacture of recombinant proteins also faces cost and production challenges. Current bioproduction systems, particularly in mammalian cell cultures, are complex, costly, and often require extensive purification to eliminate the risk of contamination. Samabriva's platform aims to provide a more cost-effective and contaminant-free production process for recombinant proteins.

The market demand for high-value molecules, both botanical and plant-derivative drugs, as well as recombinant proteins, is growing rapidly. The global botanical and plant-derivative drug market is projected to grow at an estimated CAGR of 8.58% between 2018 and 2026, while the recombinant protein market is expected to grow even faster at a CAGR of 11.2% between 2021 and 2026 (source: Marker Research Report and Mordor Intelligence).

Samabriva's groundbreaking bioproduction platform positions the company as a frontrunner in precision biomanufacturing. With the successful completion of its Series-A funding round, the company is poised for further growth and innovation. The investment will not only facilitate the establishment of an industrial production site in Belgium but also support the expansion of research and development efforts in France. Samabriva's commitment to sustainable, scalable, and high-quality production processes sets it apart in the biotech industry, positioning it as a world leader in precision biomanufacturing of complex molecules.

To learn more about Samabriva and its innovative bioproduction platform, visit their official website at samabriva.com.